Background
Babesiosis is a potentially life-threatening, tick-borne infection
endemic in New York. The purpose of this study was to review recent
trends in babesiosis management and outcomes focusing on patients,
who were treated with combination of azithromycin and atovaquone.
Methods
A retrospective chart review of patients seen at Stony Brook
University Hospital between 2008 and 2014 with peripheral blood
smears positive for Babesia was performed. Clinical and
epidemiological information was recorded and analyzed.
Results
62 patients had confirmed babesiosis (presence of parasitemia). Forty
six patients (74%) were treated exclusively with combination of
azithromycin and atovaquone; 40 (87%) of these patients were
hospitalized, 11 (28%) were admitted to Intensive Care Unit (ICU), 1
(2%) died. Majority of patients presented febrile with median
temperature 38.5 °C. Median peak parasitemia among all patients was
1.3%, and median parasitemia among patients admitted to ICU was 5.0%.
Six patients (15%) required exchange transfusion. Majority of
patients (98%) improved and were discharged from hospital or clinic.
Conclusion
Symptomatic babesiosis is still rare even in endemic regions.
Recommended treatment regimen is well tolerated and effective.
Compared to historical controls we observed a lower overall
mortality.
No comments:
Post a Comment